ArticleFrontiers in oncology2026
Case Report: Integration of intratumoral oncolytic adenovirus with total neoadjuvant therapy in metachronous locally advanced rectal cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent landmark randomized controlled trials have established total neoadjuvant therapy (TNT) as a standard treatment option for selected patients with locally advanced rectal cancer (LARC), offering improved tumor response and opportunities for organ preservation. In parallel, the integration of oncolytic virotherapy (OVT) into neoadjuvant regimens has shown potential benefits in various solid tumors. However, to date, no clinical reports have demonstrated the therapeutic efficacy of combining OVT with TNT specifically in LARC. Case presentation: We report a case of a 50-year-old patient diagnosed with metachronous LARC harboring TP53 mutation. We treated this patient with intratumoral injection of the recombinant human adenovirus H101 in combination with TNT, resulting in a pathologic complete response (pCR) and successful preservation of anal sphincter function. At the most recent follow-up, there was no evidence of local recurrence or distant metastasis. Conclusion: This case highlights the potential of oncolytic virotherapy to enhance chemotherapy and radiotherapy effects in LARC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.